vs
EXACT SCIENCES CORP（EXAS）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
Rollins, Inc.的季度营收约是EXACT SCIENCES CORP的1.0倍（$906.4M vs $878.4M），Rollins, Inc.净利率更高（11.9% vs -9.8%，领先21.7%），EXACT SCIENCES CORP同比增速更快（23.1% vs 10.2%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $111.2M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 0.8%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
EXAS vs ROL — 直观对比
营收规模更大
ROL
是对方的1.0倍
$878.4M
营收增速更快
EXAS
高出12.9%
10.2%
净利率更高
ROL
高出21.7%
-9.8%
自由现金流更多
EXAS
多$9.2M
$111.2M
两年增速更快
EXAS
近两年复合增速
0.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $906.4M |
| 净利润 | $-86.0M | $107.8M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 16.1% |
| 净利率 | -9.8% | 11.9% |
| 营收同比 | 23.1% | 10.2% |
| 净利润同比 | 90.1% | 2.5% |
| 每股收益（稀释后） | $-0.45 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASROL
| Q1 26 | — | $906.4M | ||
| Q4 25 | $878.4M | $912.9M | ||
| Q3 25 | $850.7M | $1.0B | ||
| Q2 25 | $811.1M | $999.5M | ||
| Q1 25 | $706.8M | $822.5M | ||
| Q4 24 | $713.4M | $832.2M | ||
| Q3 24 | $708.7M | $916.3M | ||
| Q2 24 | $699.3M | $891.9M |
净利润EXASROL
| Q1 26 | — | $107.8M | ||
| Q4 25 | $-86.0M | $116.4M | ||
| Q3 25 | $-19.6M | $163.5M | ||
| Q2 25 | $-1.2M | $141.5M | ||
| Q1 25 | $-101.2M | $105.2M | ||
| Q4 24 | $-864.6M | $105.7M | ||
| Q3 24 | $-38.2M | $136.9M | ||
| Q2 24 | $-15.8M | $129.4M |
毛利率EXASROL
| Q1 26 | — | — | ||
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — |
营业利润率EXASROL
| Q1 26 | — | 16.1% | ||
| Q4 25 | -9.4% | 17.5% | ||
| Q3 25 | -3.0% | 21.9% | ||
| Q2 25 | -0.3% | 19.8% | ||
| Q1 25 | -13.6% | 17.3% | ||
| Q4 24 | -122.8% | 18.1% | ||
| Q3 24 | -5.6% | 20.9% | ||
| Q2 24 | -3.8% | 20.4% |
净利率EXASROL
| Q1 26 | — | 11.9% | ||
| Q4 25 | -9.8% | 12.8% | ||
| Q3 25 | -2.3% | 15.9% | ||
| Q2 25 | -0.1% | 14.2% | ||
| Q1 25 | -14.3% | 12.8% | ||
| Q4 24 | -121.2% | 12.7% | ||
| Q3 24 | -5.4% | 14.9% | ||
| Q2 24 | -2.3% | 14.5% |
每股收益（稀释后）EXASROL
| Q1 26 | — | $0.22 | ||
| Q4 25 | $-0.45 | $0.24 | ||
| Q3 25 | $-0.10 | $0.34 | ||
| Q2 25 | $-0.01 | $0.29 | ||
| Q1 25 | $-0.54 | $0.22 | ||
| Q4 24 | $-4.69 | $0.22 | ||
| Q3 24 | $-0.21 | $0.28 | ||
| Q2 24 | $-0.09 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $116.5M |
| 总债务越低越好 | — | $650.6M |
| 股东权益账面价值 | $2.4B | $1.4B |
| 总资产 | $5.9B | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资EXASROL
| Q1 26 | — | $116.5M | ||
| Q4 25 | $964.7M | $100.0M | ||
| Q3 25 | $1.0B | $127.4M | ||
| Q2 25 | $858.4M | $123.0M | ||
| Q1 25 | $786.2M | $201.2M | ||
| Q4 24 | $1.0B | $89.6M | ||
| Q3 24 | $1.0B | $95.3M | ||
| Q2 24 | $946.8M | $106.7M |
总债务EXASROL
| Q1 26 | — | $650.6M | ||
| Q4 25 | — | $486.1M | ||
| Q3 25 | — | $485.7M | ||
| Q2 25 | — | $485.3M | ||
| Q1 25 | — | $485.5M | ||
| Q4 24 | — | $395.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益EXASROL
| Q1 26 | — | $1.4B | ||
| Q4 25 | $2.4B | $1.4B | ||
| Q3 25 | $2.5B | $1.5B | ||
| Q2 25 | $2.5B | $1.4B | ||
| Q1 25 | $2.4B | $1.4B | ||
| Q4 24 | $2.4B | $1.3B | ||
| Q3 24 | $3.2B | $1.3B | ||
| Q2 24 | $3.2B | $1.2B |
总资产EXASROL
| Q1 26 | — | $3.2B | ||
| Q4 25 | $5.9B | $3.1B | ||
| Q3 25 | $5.9B | $3.2B | ||
| Q2 25 | $5.8B | $3.2B | ||
| Q1 25 | $5.7B | $2.9B | ||
| Q4 24 | $5.9B | $2.8B | ||
| Q3 24 | $6.7B | $2.8B | ||
| Q2 24 | $6.7B | $2.8B |
负债/权益比EXASROL
| Q1 26 | — | 0.47× | ||
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | — | 0.30× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $118.4M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $111.2M |
| 自由现金流率自由现金流/营收 | 13.7% | 12.3% |
| 资本支出强度资本支出/营收 | 3.6% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 1.10× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $621.1M |
8季度趋势，按日历期对齐
经营现金流EXASROL
| Q1 26 | — | $118.4M | ||
| Q4 25 | $151.7M | $164.7M | ||
| Q3 25 | $219.9M | $191.3M | ||
| Q2 25 | $89.0M | $175.1M | ||
| Q1 25 | $30.8M | $146.9M | ||
| Q4 24 | $47.1M | $188.2M | ||
| Q3 24 | $138.7M | $146.9M | ||
| Q2 24 | $107.1M | $145.1M |
自由现金流EXASROL
| Q1 26 | — | $111.2M | ||
| Q4 25 | $120.4M | $159.0M | ||
| Q3 25 | $190.0M | $182.8M | ||
| Q2 25 | $46.7M | $168.0M | ||
| Q1 25 | $-365.0K | $140.1M | ||
| Q4 24 | $10.7M | $184.0M | ||
| Q3 24 | $112.6M | $139.4M | ||
| Q2 24 | $71.2M | $136.4M |
自由现金流率EXASROL
| Q1 26 | — | 12.3% | ||
| Q4 25 | 13.7% | 17.4% | ||
| Q3 25 | 22.3% | 17.8% | ||
| Q2 25 | 5.8% | 16.8% | ||
| Q1 25 | -0.1% | 17.0% | ||
| Q4 24 | 1.5% | 22.1% | ||
| Q3 24 | 15.9% | 15.2% | ||
| Q2 24 | 10.2% | 15.3% |
资本支出强度EXASROL
| Q1 26 | — | 0.8% | ||
| Q4 25 | 3.6% | 0.6% | ||
| Q3 25 | 3.5% | 0.8% | ||
| Q2 25 | 5.2% | 0.7% | ||
| Q1 25 | 4.4% | 0.8% | ||
| Q4 24 | 5.1% | 0.5% | ||
| Q3 24 | 3.7% | 0.8% | ||
| Q2 24 | 5.1% | 1.0% |
现金转化率EXASROL
| Q1 26 | — | 1.10× | ||
| Q4 25 | — | 1.41× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.78× | ||
| Q3 24 | — | 1.07× | ||
| Q2 24 | — | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
ROL
暂无分部数据
